1. Home
  2. APRE vs SYTA Comparison

APRE vs SYTA Comparison

Compare APRE & SYTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APRE
  • SYTA
  • Stock Information
  • Founded
  • APRE 2006
  • SYTA N/A
  • Country
  • APRE United States
  • SYTA Canada
  • Employees
  • APRE N/A
  • SYTA N/A
  • Industry
  • APRE Biotechnology: Biological Products (No Diagnostic Substances)
  • SYTA Telecommunications Equipment
  • Sector
  • APRE Health Care
  • SYTA Telecommunications
  • Exchange
  • APRE Nasdaq
  • SYTA Nasdaq
  • Market Cap
  • APRE 10.0M
  • SYTA 10.7M
  • IPO Year
  • APRE 2019
  • SYTA 2020
  • Fundamental
  • Price
  • APRE $1.80
  • SYTA $3.40
  • Analyst Decision
  • APRE Strong Buy
  • SYTA
  • Analyst Count
  • APRE 2
  • SYTA 0
  • Target Price
  • APRE $15.50
  • SYTA N/A
  • AVG Volume (30 Days)
  • APRE 50.9K
  • SYTA 2.8M
  • Earning Date
  • APRE 08-11-2025
  • SYTA 08-15-2025
  • Dividend Yield
  • APRE N/A
  • SYTA N/A
  • EPS Growth
  • APRE N/A
  • SYTA N/A
  • EPS
  • APRE N/A
  • SYTA N/A
  • Revenue
  • APRE $1,284,475.00
  • SYTA $11,740,024.00
  • Revenue This Year
  • APRE N/A
  • SYTA $18.41
  • Revenue Next Year
  • APRE N/A
  • SYTA N/A
  • P/E Ratio
  • APRE N/A
  • SYTA N/A
  • Revenue Growth
  • APRE 33.27
  • SYTA 33.58
  • 52 Week Low
  • APRE $1.41
  • SYTA $0.93
  • 52 Week High
  • APRE $5.01
  • SYTA $162.90
  • Technical
  • Relative Strength Index (RSI)
  • APRE 49.58
  • SYTA 57.85
  • Support Level
  • APRE $1.64
  • SYTA $1.79
  • Resistance Level
  • APRE $1.81
  • SYTA $3.73
  • Average True Range (ATR)
  • APRE 0.15
  • SYTA 0.38
  • MACD
  • APRE -0.01
  • SYTA 0.14
  • Stochastic Oscillator
  • APRE 51.76
  • SYTA 82.14

About APRE Aprea Therapeutics Inc. Common stock

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

About SYTA Siyata Mobile Inc.

Siyata Mobile Inc is engaged in the sale of vehicle mounted, cellular-based communications platforms over advanced 3G (Third generation) mobile networks and cellular booster systems. The company develops, markets and sells a portfolio of rugged handheld Push-to-Talk over Cellular (PoC) smartphone devices. These rugged business-to-business (B2B) environments are focused on enterprise customers, first responders, construction workers, security guards, government agencies, utilities, transportation and waste management, amusement parks, and mobile workers in multiple industries. The company operates in USA, Canada, EMEA and Australia. It derives maximum revenue from USA.

Share on Social Networks: